Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
February 22, 2024
The process of discovering, producing, buying, and consuming antibiotics is riddled with market and government failures. To solve antibiotic resistance, it’s not enough to solve just some of these. If we fix the market failures that reduce the number of new antibiotics that are discovered, but not t...
WORKING PAPERS
February 22, 2024
Antibiotic resistance (ABR) already contributes to almost five million deaths per year. Without action, this number will likely rise substantially. We provide the first comprehensive assessment of the economic drivers of ABR, arguing that ABR in large part arises from extensive unresolved market (an...
BRIEFS
June 08, 2023
To meet many of today’s most pressing challenges, we need to find new solutions. But the fastest, cheapest, and most effective way to encourage high-impact innovation isn’t always obvious. Governments, philanthropists, and the private sector typically invest in research and development (R&D) by bett...
Blog Post
December 16, 2022
In 2020, we opened our end-of-year review by saying that “Not even Dr. Pangloss could put a positive spin on… a historic dumpster fire of a year.” The next year, we described 2021 as “not quite the best of times, not quite the worst of times”, which seemed like progress. But if we take one lesson fr...
Blog Post
June 04, 2021
Since March of 2020, COVID-19 changed most aspects of life as we knew it, from our personal day-to-day activities to the systems, processes, and structures that keep the global economy interconnected and moving. This included pharmaceutical production and distribution, where anecdotal evidence ...
CGD NOTES
December 07, 2020
The SARS-COV-2/COVID-19 pandemic has created an unprecedented public health challenge, spurring a global race to develop and distribute viable vaccines. By mid-2021, there will likely be multiple licensed vaccines. Although there is an urgent need for these vaccines to be made available, several cri...